RxSight, Inc.
$7.44
▲
4.73%
2026-04-21 09:15:00
rxsight.com
NGM: RXST
Explore RxSight, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$314.04 M
Current Price
$7.44
52W High / Low
$16.74 / $5.9
Stock P/E
—
Book Value
$6.68
Dividend Yield
—
ROCE
-16.88%
ROE
-13.98%
Face Value
—
EPS
$-0.95
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
461
Beta
1.21
Debt / Equity
4
Current Ratio
10.95
Quick Ratio
9.75
Forward P/E
-14.16
Price / Sales
2.1
Enterprise Value
$64.76 M
EV / EBITDA
-1.44
EV / Revenue
0.48
Rating
None
Target Price
$10.21
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Vivos Therapeutics, Inc. | $1.01 | — | $13.14 M | — | -108.39% | -3.35% | $7.95 / $0.96 | $0.31 |
| 2. | Bioventus Inc. | $10.28 | 38.48 | $874.79 M | — | 10.76% | 13.17% | $10.76 / $5.81 | $2.74 |
| 3. | NeuroPace, Inc. | $16.53 | — | $545.07 M | — | -18.62% | -1.59% | $18.98 / $7.56 | $0.57 |
| 4. | Avanos Medical, Inc. | $24.64 | — | $1.15 B | — | 1.7% | -9.07% | $24.72 / $9.3 | $16.75 |
| 5. | Beta Bionics, Inc. | $12.91 | — | $576.08 M | — | -24.07% | -40.26% | $32.71 / $8.8 | $6.48 |
| 6. | UFP Technologies, Inc. | $201.08 | 22.53 | $1.54 B | — | 16.02% | 17.82% | $274.93 / $182.87 | $54.95 |
| 7. | Myomo, Inc. | $0.9 | — | $34.65 M | — | -47.54% | -86.24% | $4.99 / $0.6 | $0.3 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 32.61 M | 30.34 M | 33.64 M | 37.9 M | 40.21 M | — |
| Operating Profit | -11.34 M | -12.18 M | -14 M | -10.67 M | -8.63 M | — |
| Net Profit | -9.15 M | -9.82 M | -11.79 M | -8.19 M | -5.94 M | — |
| EPS in Rs | -0.22 | -0.24 | -0.29 | -0.2 | -0.14 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 134.48 M | 139.93 M | 89.08 M | 49.01 M |
| Operating Profit | -48.19 M | -36.86 M | -50.09 M | -63.32 M |
| Net Profit | -38.94 M | -27.45 M | -48.61 M | -66.76 M |
| EPS in Rs | -0.94 | -0.67 | -1.18 | -1.62 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 311.81 M | 318.56 M | 182.55 M | 150.16 M |
| Total Liabilities | 36.13 M | 37.33 M | 22.19 M | 60.26 M |
| Equity | 275.68 M | 281.24 M | 160.36 M | 89.9 M |
| Current Assets | 287.46 M | 293.82 M | 168.41 M | 134.56 M |
| Current Liabilities | 26.25 M | 25.88 M | 20.9 M | 17.24 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -15.51 M | -16.95 M | -41.59 M | -58.85 M |
| Investing CF | 16.89 M | -99.31 M | -22.13 M | 39.95 M |
| Financing CF | 1.86 M | 123.32 M | 61.52 M | 6.33 M |
| Free CF | -19.34 M | -22.39 M | -46.41 M | -61.24 M |
| Capex | -3.83 M | -5.44 M | -4.81 M | -2.39 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 57.09% | 81.77% | — | — |
| Earnings Growth % | 43.52% | 27.19% | — | — |
| Profit Margin % | -19.62% | -54.57% | -136.22% | — |
| Operating Margin % | -26.34% | -56.23% | -129.21% | — |
| Gross Margin % | 70.71% | 60.36% | 43.52% | — |
| EBITDA Margin % | -17.02% | -46.25% | -117.9% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.